Galvus

Uses
Galvus (Vildagliptin) belongs to a drugs with a hypoglycemic effect, which is achieved by increasing insulin secretion and reducing glucagon release.

Galvus (Vildagliptin) is a stimulator of the pancreas insular apparatus, selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Rapid and complete inhibition of the activity of DPP-4 (> 90%) causes an increase in both basal and food-stimulated secretion of glucagon-like type 1 peptide (GLP-1).

Increasing the concentration of GLP-1, Galvus (Vildagliptin) causes an increase in the sensitivity of pancreas β-cells to glucose, which leads to an improvement in glucose-dependent insulin secretion.

With using vildagliptin 50–100 mg / day in patients with type 2 diabetes mellitus (DM), an improvement in the function of β-cells of the pancreas is noted. The degree of improvement in β-cell function depends on the degree of their initial damage; so in persons not suffering from diabetes (with a normal concentration of glucose in the blood plasma), vildagliptin does not stimulate insulin secretion and does not reduce the level of glucose.

By increasing the concentration of endogenous GLP-1, vildagliptin increases the sensitivity of α-cells to glucose, which leads to an improvement in glucose-dependent regulation of glucagon secretion.

Dosage and Administration
Always follow your doctor`s instructions when using Galvus (Vildagliptin) to get the safest and most effective results from treatment. The dosage is prescribed by the doctor individually for each patient.

When Galvus (Vildagliptin) used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and in combination with insulin (with or without metformin), the recommended daily dose is 100 mg, which is divided into two doses: 50 mg in the morning and 50 mg in the evening.

Side effects
When using Galvus (Vildagliptin) as monotherapy or in combination with other drugs, most adverse reactions were mild, temporary, and did not require discontinuation of therapy. The correlation between the incidence of side effects and age, sex, ethnicity, duration of use or dosing regimen was not detected.

• Dizziness
• Headache
• Tremor
• Asthenia
• Nausea
• Flatulence
• Constipation
• Peripheral edema
• Hyperhidrosis
• Hypoglycemia

You must tell your doctor as soon as possible if any side effects occur. If any severe side effects are noticed, you must immediately consult your doctor.

Precautions
Influence on ability to drive vehicles and / or work with mechanisms.

The effect of Galvus (Vildagliptin) on the ability to drive or operate machinery has not been established. With the development of dizziness on the background of drug treatment patients should not drive a car or work with mechanisms.